The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Therapeutics, Inc. | COM | 00461U105 | 29,119,313 | 2,808,034 | SH | SOLE | 2,808,034 | 0 | 0 | |||
| Cymabay Therapeutics, Inc. | COM | 23257D103 | 19,568,679 | 1,787,094 | SH | SOLE | 1,787,094 | 0 | 0 | |||
| Kinnate Biopharma Inc. | COM | 49705R105 | 29,305,078 | 9,671,643 | SH | SOLE | 9,671,643 | 0 | 0 | |||
| Kura Oncology, Inc. | COM | 50127T109 | 19,572,439 | 1,849,947 | SH | SOLE | 1,849,947 | 0 | 0 | |||
| Lyell Immunopharma, Inc. | COM | 55083R104 | 30,846,000 | 9,700,000 | SH | SOLE | 9,700,000 | 0 | 0 | |||
| Pharvaris N.V. | COM | N69605108 | 56,675,833 | 3,743,450 | SH | SOLE | 3,743,450 | 0 | 0 | |||
| Syndax Pharmaceuticals, Inc. | COM | 87164F105 | 18,313,750 | 875,000 | SH | SOLE | 875,000 | 0 | 0 | |||